Health Condition 1: N200- Calculus of kidney
Conditions
Interventions
Intervention1: Dawa-e-Gurda (Powder): Dawa-e-Gurda (Powder)in the dose of 3gm twice daily with water after meals.
Control Intervention1: Not Applicable: Not Applicable
Sponsors
Central Research Institute of Unani Medicine Hyderabad
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients of any sex aged 18-65 years 2) Patients with Has ?h al-Kulya (nephrolithiasis) diagnosed by Plain X-Ray Abdomen (KUB)/ Ultrasound Abdomen 3) Stone in Renal Pelvis with size ranging from 5-9 mm 4) Patients with or without any of the following symptoms: -Bawl al-Dam (Haematuria) -Siql al-Kh ?sira (Heaviness in the Loin) -Waja‘ al-Kh ?sira (Pain in the Loin) -Urine showing Calcium Crystalluria -History of Recurrent UTI -History of Recurrent Nephrolithiasis 5) Patients willing to give written informed consent 6) Patients willing to comply with the requirements of the study protocol
Exclusion criteria
Exclusion criteria: 1) Patients aged less than 18 or more than 65 years 2) Patients having acute renal colic 3) Complicated cases of nephrolithiasis requiring surgical intervention 4) Patients with hydronephrosis, acute symptoms of UTI or any other kidney disease, including serum creatinine level more than 1.5 x ULN or eGFR less than 60 mL/min 5) Liver dysfunction, defined as serum bilirubin more than 1.5 x ULN, SGOT (AST) or SGPT (ALT) more than 2.5 x ULN 6) Known cases of significant cardiac/ pulmonary dysfunction or immunocompromised states (HIV/ AIDS, etc.)/ malignancies 7) Patients on long-term medications 8) Pregnancy and lactation 9) Currently active alcohol or drug abuse/ history of alcohol or drug abuse within 6 months prior to baseline 10) Known sensitivity to study medication or any of its ingredient 11) Patient not willing to attend treatment schedule regularly
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Stone Size on Ultrasound (KUB) 2) Renal Pain and Loin Heaviness 3) Visual Analogue Scale (VAS) 4) Relief in Bawl al-Dam (Haematuria) Timepoint: USG at Baseline and 8th week. Rest at Baseline, 2nd week, 4th week, 6th week, 8th week | — |
Secondary
| Measure | Time frame |
|---|---|
| Lab InvestigationsTimepoint: Baseline and after treatment. | — |
Countries
India
Contacts
Public ContactDr Mohd Nawab
Central Research Institute Of Unani Medicine - Hyderabad.
Outcome results
None listed